Trial reportPloS one2017
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- IgG4-related disease with multiorgan involvement: a case-based review.Rheumatology international · 2021Pooled it
- Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review.Neurology(R) neuroimmunology & neuroinflammation · 2019Pooled it
- IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.Kidney international reports · 2026Review
- Article
- Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.Rheumatology and therapy · 2026Article
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
- Recurrent IgG4 Disease-Related Tubulointerstitial Nephritis Treated With Rituximab As Maintenance Therapy.Cureus · 2026Article
- Long-term treatment patterns and outcomes in IgG4-related disease - a retrospective single-center cohort study focusing on rituximab.Rheumatology international · 2026Article
- A case of an immunoglobulin G4 related inflammatory pseudotumor involving the clivus and the nasopharynx: A challenging case of a perplexing entity with an exhaustive overview.Brain & spine · 2026Article
- Cornea biomechanics and biometric evaluations in immunoglobulin G4-related ophthalmic disease.PloS one · 2026Article
- Recurrent IgG4-related Tubulointerstitial Nephritis Successfully Treated With Obinutuzumab: A Case Report and Literature Review.Kidney medicine · 2026Article
- Case Report: A case of primary IgG4-related skin disease presenting initially with skin papules and abscesses.Frontiers in immunology · 2026Article
- Coronary periarteritis in IgG4-RD: A case series.Clinical rheumatology · 2025Article
- IgG4-Related Disease: A Case Series Highlighting Diverse Clinical Manifestations and Treatment Outcomes.Cureus · 2025Article
- Immunoglobulin G4-related lung disease mistaken for pulmonary tuberculosis: A case report.World journal of clinical cases · 2025Article
- New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach.Journal of clinical medicine · 2025Review
- Use of Rituximab in the Management of a Nasopharyngeal Fibrosing Inflammatory Pseudotumor.Clinical case reports · 2025Article
- [Anti-CD19 treatment: the new gold standard for IgG4-related diseases].Zeitschrift fur Rheumatologie · 2025Review
- Immunosuppressants for IgG4-related disease.The Cochrane database of systematic reviews · 2025Article
- C3 Glomerulonephritis Associated With Unusual IgG4 Antifactor H in IgG4-related Disease.Kidney medicine · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess efficacy and safety of rituximab (RTX) as induction therapy, maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) patients.
methodsNationwide retrospective multicenter study of IgG4-RD patients treated with at least one course of RTX. Clinical, biological and radiological response, relapse rate and drug tolerance were analyzed. Kaplan-Meier curves were plotted and risk factors for relapse studied with a Cox regression model.
resultsAmong 156 IgG4-RD patients included in the French database, 33 received rituximab. Clinical response was noted in 29/31 (93.5%) symptomatic patients. Glucocorticoids withdrawal was achieved in 17 (51.5%) patients. During a mean follow-up of 24.8 ±21 months, 13/31 (41.9%) responder patients relapsed after a mean delay of 19 ±11 months after RTX. Active disease, as defined by an IgG4-RD Responder Index >9 before RTX, was significantly associated with relapse (HR = 3.68, 95% CI: 1.1, 12.6) (P = 0.04), whereas maintenance therapy with systematic (i.e. before occurrence of a relapse) RTX retreatment was associated with longer relapse-free survival (41 versus 21 months; P = 0.02). Eight severe infections occurred in 4 patients during follow-up (severe infections rate of 12.1/100 patient-years) and hypogammaglobulinemia ≤5 g/l in 3 patients.
conclusionRTX is effective for both induction therapy and treatment of relapses in IgG4-RD, but relapses are frequent after B-cell reconstitution. Maintenance therapy with systematic RTX infusions is associated with longer relapse-free survival and might represent a novel treatment strategy. Yet, the high rate of infections and the temporary effect of RTX might be hindrances to such strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.